Chiesi announces new senior level changes to leadership team

Privately-held Italian drugmaker Chiesi Farmaceutici today announced the appointment of Ralph Blom as the general manager for Chiesi Limited (covering the UK and Ireland), beginning January 2024.

Mr Blom will succeed Tom Delahoyde, who will retire at the end of December 2023. David Garzón Lafuente will also join as the Rare Disease Business Unit lead in January 2024.

“It’s an honor to step into Tom’s shoes, who has built such a strong foundation, and I am very excited to continue building upon this, prioritising patient care, driving our sustainability agenda and fostering a culture of excellence,” said Mr Blom, adding: “We have a clear vision: be the point of reference for all stakeholders in the therapeutic areas we are active in, the company to turn to when you want to get things done. Together with our exceptional team, we will continue to deliver high-quality therapeutic solutions and uphold the values that define Chiesi.”